ACTH (Adrenocorticotropic Hormone) Dosage Guide

Evidence-based protocols for ACTH and Cosyntropin (ACTH 1–24) — diagnostic stimulation testing, low-dose research protocols for adrenal support, cortisol modulation, melanocortin pathway activity, and safety considerations.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

ACTH

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is ACTH?

ACTH (Adrenocorticotropic Hormone) is a 39 amino acid peptide hormone produced by the anterior pituitary gland. It is the primary regulator of cortisol synthesis in the human body — when the brain detects a need for cortisol (stress response, circadian rhythm, inflammation), the hypothalamus releases CRH (corticotropin-releasing hormone), which triggers the pituitary to secrete ACTH into the bloodstream. ACTH then travels to the adrenal cortex, where it binds to the MC2R (melanocortin 2 receptor) and stimulates the production and release of cortisol, aldosterone, and adrenal androgens.

Cosyntropin (also known as tetracosactide or Synacthen) is the synthetic diagnostic fragment of ACTH containing only the first 24 amino acids (ACTH 1–24). This fragment retains full biological activity because the MC2R binding domain resides entirely within the first 24 residues. Cosyntropin is the form used in clinical medicine for the ACTH stimulation test — the gold standard diagnostic procedure for assessing adrenal gland function and detecting adrenal insufficiency.

Beyond its established diagnostic role, ACTH has attracted research interest for its involvement in the melanocortin signaling system, HPA axis modulation, and potential low-dose adrenal support protocols. ACTH is derived from the precursor protein POMC (proopiomelanocortin), the same precursor that produces α-MSH, β-endorphin, and other melanocortin peptides. This shared lineage gives ACTH cross-reactivity with melanocortin receptors beyond MC2R — including MC1R (pigmentation) and MC4R (appetite and energy balance).

Use our Peptide Dosage to calculate your exact subcutaneous dose based on vial size and concentration.

Dosing information in this guide is derived from published research and community protocols.

Key Characteristics:

39 amino acid pituitary hormone (full-length ACTH 1–39) — the primary endogenous regulator of cortisol production; secreted by the anterior pituitary in response to CRH from the hypothalamus
Cosyntropin (ACTH 1–24) is the synthetic diagnostic fragment — retains full MC2R binding activity; used clinically for the ACTH stimulation test to assess adrenal function
MC2R receptor activation on adrenal cortex — stimulates steroidogenesis — production of cortisol, aldosterone, and adrenal androgens (DHEA)
Cross-reactivity with other melanocortin receptors — affinity for MC1R (pigmentation), MC3R, MC4R (appetite/energy), and MC5R (exocrine); explains hyperpigmentation with chronic use
Short half-life (~10 minutes for ACTH 1–39) — rapid clearance; Cosyntropin (1–24) is slightly more stable but still acts within a narrow time window
HPA axis feedback loop involvement — exogenous ACTH raises cortisol, which feeds back to suppress endogenous ACTH production; chronic use risks HPA axis suppression

For a complete overview of its biology and research, see our full ACTH profile. New to peptides? Start with the Beginner's Guide to Peptides.

How ACTH Dosage Is Determined

ACTH dosing is uniquely well-characterized compared to most research peptides because Cosyntropin has been used clinically for decades as a diagnostic agent. The standard and low-dose stimulation test protocols are established in endocrinology literature. Research and community-derived protocols for non-diagnostic use are less standardized and carry greater uncertainty.

Standard Cosyntropin Stimulation Test (250 mcg)

The standard-dose ACTH stimulation test was established in the 1960s and remains the gold standard for diagnosing primary adrenal insufficiency (Addison's disease). The 250 mcg IV or IM dose produces supraphysiological ACTH levels — approximately 100x the physiological maximum — to maximally stimulate the adrenal cortex. Cortisol is measured at baseline, 30 minutes, and 60 minutes. A peak cortisol ≥18–20 mcg/dL (500–550 nmol/L) indicates adequate adrenal reserve.

Low-Dose Cosyntropin Test (1 mcg)

The low-dose (1 mcg) ACTH stimulation test was developed to improve sensitivity for detecting secondary adrenal insufficiency and partial adrenal impairment. At 1 mcg IV, the adrenals receive a more physiological stimulus, and patients with borderline adrenal reserve who pass the 250 mcg test may fail the 1 mcg test. The low-dose protocol requires precise dilution from a 250 mcg vial and has generated some controversy regarding standardization, but multiple studies support its utility for detecting subtle HPA axis suppression.

Research & Community Protocols

Outside diagnostic testing, some researchers and community practitioners have explored low-dose ACTH protocols (typically 1–50 mcg SubQ) for gentle adrenal stimulation. The rationale is to provide a mild physiological stimulus to adrenal tissue without the sustained cortisol elevation of repeated full-dose stimulation. These protocols are experimental, not supported by randomized controlled trials, and should only be attempted under medical supervision with cortisol monitoring.

Melanocortin Pathway Research

ACTH's cross-reactivity with melanocortin receptors (MC1R, MC3R, MC4R, MC5R) has generated research interest in its broader immunomodulatory and anti-inflammatory potential beyond cortisol production. The melanocortin system plays roles in inflammation, immune modulation, energy homeostasis, and neuroprotection. However, because ACTH's primary and most potent effect is cortisol stimulation via MC2R, the endocrine consequences dominate any protocol — making it impractical to target melanocortin effects without simultaneously affecting cortisol.

Strength of evidence: Strong for diagnostic use, limited for research protocols. The Cosyntropin stimulation test has decades of clinical validation and is a standard endocrinology procedure. Low-dose ACTH research protocols for non-diagnostic purposes are experimental with limited published data. Community protocols are anecdotal. ACTH is NOT in the same evidence category as simple research peptides — it is a clinically used hormone with well-known endocrine effects.

Standard ACTH / Cosyntropin Dosage Ranges

ACTH dosing spans a wide range depending on the context — from the supraphysiological 250 mcg diagnostic dose down to single-digit microgram research protocols. Understanding the purpose and risk profile of each range is critical.

Diagnostic Protocols (Cosyntropin Stimulation Test)

Protocol	Dose	Route	Cortisol Measurement	Notes
Standard-Dose Test	250 mcg	IV or IM	Baseline, 30 min, 60 min	Gold standard; supraphysiological stimulus; detects primary adrenal insufficiency
Low-Dose Test	1 mcg	IV only	Baseline, 20 min, 30 min	More physiological stimulus; may detect subtle/secondary adrenal insufficiency; requires precise dilution

Research / Community Protocols (Experimental)

Level	Dose	Route	Frequency	Notes
Ultra-Low Research	1–5 mcg	SubQ or IV	1–3x per week	Minimal adrenal stimulus; closest to physiological range; least risk
Low-Dose Research	10–25 mcg	SubQ	2–3x per week	Moderate adrenal stimulus; cortisol monitoring required every 2 weeks
Moderate Research	25–50 mcg	SubQ or IM	2–3x per week	Stronger adrenal stimulus; higher cortisol elevation risk; close medical supervision essential

All non-diagnostic ACTH use is experimental. The research and community dosage ranges above are not derived from approved pharmaceutical protocols. They carry real endocrine risks including cortisol elevation, HPA axis suppression, and metabolic effects. Cortisol blood testing before, during, and after any protocol is mandatory — not optional. Medical supervision is required.

Administration Routes Compared

ACTH / Cosyntropin is administered parenterally (by injection). Oral administration is not viable because the 39 amino acid peptide (or 24 amino acid Cosyntropin fragment) is rapidly degraded by digestive enzymes. The three relevant routes are intravenous, intramuscular, and subcutaneous — each with distinct pharmacokinetic characteristics.

Parameter	Intravenous (IV)	Intramuscular (IM)	Subcutaneous (SubQ)
Onset of Action	Fastest (minutes)	Moderate (15–30 min)	Slowest (20–40 min)
Peak Cortisol Response	30 min	45–60 min	60–90 min
Bioavailability	100%	High (~95%)	High (~90%)
Primary Use	Diagnostic testing (standard & low-dose)	Diagnostic testing (standard dose)	Research protocols (low-dose)
Duration of Effect	Shortest (sharp peak, rapid decline)	Moderate	Longest (slower absorption, more sustained)
Ease of Administration	Requires clinical setting	Clinical or experienced practitioner	Easiest (self-administrable)
Community Use	Clinical only	Uncommon in community	Most common research route

Why SubQ for research protocols: Subcutaneous injection provides a slower, more sustained absorption profile compared to IV, which creates a gentler cortisol stimulus rather than the sharp spike-and-decline seen with IV administration. For low-dose research protocols aiming at mild adrenal stimulation, this sustained release profile is preferred. IV remains the standard for diagnostic testing because the sharp, predictable cortisol response allows precise timing of blood draws.

Calculate Your ACTH Dose

Cosyntropin is typically supplied in 250 mcg vials as lyophilized powder. For the standard 250 mcg diagnostic test, the entire vial is reconstituted and used. For low-dose protocols, precise dilution is critical — errors in dilution are the most common source of dosing inaccuracy with ACTH.

Worked Example (Low-Dose Research Protocol):

Vial size: 250 mcg of Cosyntropin
Bacteriostatic water added: 2.5 mL
Concentration: 250 mcg ÷ 2.5 mL = 100 mcg per mL
Target dose: 10 mcg
Volume to draw: 10 ÷ 100 = 0.1 mL = 10 units on an insulin syringe

Quick Reference — 250 mcg Vial

Bac Water Added	Concentration	10 mcg Dose	25 mcg Dose
1 mL	250 mcg/mL	4 units (0.04 mL)	10 units (0.1 mL)
2.5 mL	100 mcg/mL	10 units (0.1 mL)	25 units (0.25 mL)
5 mL	50 mcg/mL	20 units (0.2 mL)	50 units (0.5 mL)
10 mL	25 mcg/mL	40 units (0.4 mL)	100 units (1.0 mL)

Dilution accuracy is critical. For low-dose protocols (1–10 mcg), errors in reconstitution can result in 10–100x dosing errors. Use a calibrated syringe, reconstitute slowly to avoid foaming, and consider serial dilution for ultra-low doses. Always verify your math before drawing the dose.

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

ACTH Dosage by Goal

ACTH protocols vary dramatically depending on whether the goal is diagnostic testing, gentle adrenal stimulation, or research into melanocortin signaling. The cortisol implications of each protocol are fundamentally different.

Diagnostic: Adrenal Function Assessment (Standard)

The standard ACTH stimulation test is a one-time diagnostic event performed in a clinical setting. It is the gold standard for diagnosing primary adrenal insufficiency (Addison's disease) and is also used post-operatively after pituitary surgery or to assess patients on chronic corticosteroid therapy.

Dose: 250 mcg Cosyntropin
Route: IV (bolus) or IM
Protocol: Draw baseline cortisol; administer dose; draw cortisol at 30 and 60 minutes
Normal response: Peak cortisol ≥18–20 mcg/dL
Setting: Clinical only; performed by endocrinologist or trained provider

Diagnostic: Subtle Adrenal Insufficiency (Low-Dose)

The low-dose test is used when there is clinical suspicion of secondary adrenal insufficiency or partial adrenal impairment that may not be detected by the standard 250 mcg test. It is particularly useful for patients with recent pituitary injury, those tapering off long-term corticosteroids, or suspected early-stage HPA axis suppression.

Dose: 1 mcg Cosyntropin
Route: IV only (precise dilution required)
Protocol: Draw baseline cortisol; administer dose; draw cortisol at 20 and 30 minutes
Key advantage: More sensitive for detecting partial adrenal reserve loss
Setting: Clinical only; requires careful dilution technique

Research: Low-Dose Adrenal Support (Experimental)

Some community protocols explore very low-dose ACTH for gentle, periodic adrenal stimulation in individuals with suspected HPA axis suppression (e.g., from long-term stress, post-corticosteroid taper, or chronic illness). The theory is that low-dose ACTH provides a physiological “training stimulus” to the adrenal cortex without causing sustained cortisol excess. This approach is highly experimental.

Dose: 5–25 mcg Cosyntropin
Route: SubQ
Frequency: 2–3x per week (not daily)
Duration: 2–4 weeks maximum; reassess with cortisol testing
Monitoring: Morning cortisol, ACTH levels, DHEA-S, glucose, blood pressure every 2 weeks
Medical supervision: Required — not a self-directed protocol

Research: Melanocortin Pathway Investigation

ACTH's activity at MC1R, MC3R, MC4R, and MC5R has generated interest in its anti-inflammatory and immunomodulatory properties through the broader melanocortin system. However, because MC2R (cortisol production) is ACTH's highest-affinity target, it is practically impossible to engage other melanocortin receptors with ACTH without simultaneously driving cortisol production. For targeted melanocortin effects without cortisol elevation, other melanocortin peptides (e.g., α-MSH fragments like KPV) are more appropriate.

ACTH is not appropriate for targeting melanocortin effects alone. If your research interest is anti-inflammatory melanocortin signaling without cortisol elevation, consider peptides like KPV (which inhibits NF-κB without activating MC2R) or other selective melanocortin receptor modulators. ACTH will always stimulate cortisol as its primary effect.

Cycling & Duration

Cycling considerations for ACTH are fundamentally different from most research peptides. The primary concern is not receptor desensitization (as with GHRPs) but rather HPA axis suppression. Chronic exogenous ACTH elevates cortisol, which feeds back to suppress the hypothalamus and pituitary, potentially leading to atrophy of the normal ACTH production pathway. This makes duration limits and tapering protocols critically important.

Protocol Type	Duration	Frequency	Notes
Diagnostic (Single Use)	One-time event	N/A	No cycling needed; single administration for adrenal function assessment
Low-Dose Research (Short Course)	2–4 weeks	2–3x per week	Maximum recommended duration for experimental protocols; cortisol monitoring required throughout
Recovery Period	4–8 weeks off	N/A	Allow HPA axis to normalize; monitor morning cortisol during recovery to confirm adrenal function
Taper Protocol	1–2 weeks taper	Reduce frequency, then stop	For any protocol lasting >2 weeks; do not stop abruptly; reduce from 3x to 2x to 1x per week before stopping

HPA axis suppression is the primary risk of extended use. Unlike peptides like BPC-157 or KPV where cycling is recommended but not critical, ACTH cycling limits exist for genuine medical safety reasons. Chronic ACTH use can suppress your body's natural ACTH production. If you stop abruptly after prolonged use, your adrenals may not receive adequate stimulation, leading to adrenal insufficiency — a potentially dangerous condition requiring emergency medical treatment. Always taper.

When to Extend or Shorten a Protocol

Never extend beyond 4 weeks without comprehensive endocrine evaluation by a qualified physician. Even 4 weeks carries HPA suppression risk at anything above ultra-low doses.
Shorten to 2 weeks or less if cortisol levels exceed the normal range on monitoring blood work, if any Cushingoid signs appear (facial puffiness, weight gain, mood changes, elevated blood sugar), or if blood pressure rises.
Stop immediately and consult a physician if you develop signs of cortisol excess: rapid weight gain, facial swelling, persistent insomnia, marked mood changes, fasting glucose consistently above normal, or new-onset hypertension.
Always taper rather than stopping abruptly for any protocol that lasted more than 2 weeks. Reduce administration frequency over 1–2 weeks before discontinuation.

ACTH Stacking Protocols

Stacking with ACTH is less common than with other research peptides because ACTH's cortisol-stimulating effects introduce significant endocrine complexity. Any stack involving ACTH must account for the cortisol elevation and its downstream metabolic effects. The stacks below represent rational combinations explored in research and community contexts, but all carry the baseline risks of ACTH use.

ACTH + Thymosin Alpha-1 — Adrenal & Immune Support

Combines low-dose ACTH for gentle adrenal stimulation with Thymosin Alpha-1 for adaptive immune system modulation. The rationale is to support adrenal function while simultaneously enhancing immune surveillance and T-cell activity — relevant for individuals dealing with both adrenal underperformance and immune compromise (e.g., post-illness recovery, chronic stress states).

Compound	Dose	Route	Purpose
ACTH (Cosyntropin)	10–25 mcg, 2–3x per week	SubQ	Low-dose adrenal stimulation; cortisol modulation
Thymosin Alpha-1	1.6 mg, 2–3x per week	SubQ	T-cell modulation; adaptive immune enhancement; immune surveillance

Protocol note: Cortisol has immunosuppressive properties at elevated levels, which could theoretically counteract Thymosin Alpha-1's immune-enhancing effects. Keep ACTH doses in the low range and monitor cortisol levels to ensure they remain within the physiological range. The goal is gentle adrenal support, not cortisol excess.

ACTH + Selank — Adrenal Support & Stress/Anxiety Modulation

Pairs low-dose ACTH for adrenal stimulation with Selank for anxiolytic and stress-modulating effects. Selank is a synthetic peptide analog of tuftsin with documented effects on GABA, serotonin, and BDNF pathways. This combination may be relevant for individuals whose adrenal underperformance is associated with chronic stress and anxiety.

Compound	Dose	Route	Purpose
ACTH (Cosyntropin)	5–15 mcg, 2–3x per week	SubQ	Gentle adrenal stimulation; cortisol normalization
Selank	250–500 mcg, 1x daily	Intranasal or SubQ	Anxiolytic; GABA modulation; BDNF upregulation; stress resilience

ACTH + BPC-157 — Adrenal Support & Tissue Repair

Combines low-dose ACTH with BPC-157 for individuals seeking adrenal support alongside tissue repair benefits. BPC-157's gastroprotective and tissue-healing properties may also help mitigate potential GI effects of cortisol elevation, as cortisol can impair gut mucosal integrity at sustained elevated levels.

Compound	Dose	Route	Purpose
ACTH (Cosyntropin)	10–25 mcg, 2–3x per week	SubQ	Low-dose adrenal stimulation; cortisol modulation
BPC-157	250–500 mcg, 1–2x daily	SubQ or Oral	Tissue repair; gastroprotection; angiogenesis; growth factor support

All ACTH stacks require cortisol monitoring. Regardless of what you combine ACTH with, the cortisol-stimulating effect remains. No stacking partner eliminates or neutralizes the endocrine risks of ACTH. Monitor cortisol, blood glucose, blood pressure, and electrolytes throughout any protocol. Medical supervision is required.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Significant endocrine risks. ACTH is fundamentally different from most research peptides in its risk profile. It directly stimulates cortisol production via the HPA axis — one of the body's most powerful hormonal systems. Single diagnostic doses are well-tolerated, but repeated or chronic use carries real risks of cortisol excess, HPA axis suppression, and metabolic complications. This is not a peptide for unsupervised experimentation.

Side Effects of Single Diagnostic Doses (250 mcg or 1 mcg)

Generally well-tolerated:

Transient facial flushing — common, resolves within minutes to hours
Mild injection site discomfort — standard for any IM or IV injection
Rare allergic reactions — very uncommon but possible (urticaria, anaphylaxis); more likely with animal-derived ACTH preparations (historical) than synthetic Cosyntropin
Brief cortisol elevation — by design (the diagnostic purpose); returns to baseline within hours

Side Effects of Repeated / Chronic Use

Cortisol excess (Cushing's-like effects) with prolonged or high-dose use:

Weight gain, especially central/abdominal obesity and “moon face”
Elevated blood glucose and insulin resistance
Hypertension (cortisol increases sodium retention and vascular tone)
Muscle wasting and proximal weakness
Bone loss (osteoporosis) — cortisol inhibits osteoblast activity
Skin thinning, easy bruising, poor wound healing
Immune suppression — increased infection susceptibility
Mood disturbances — anxiety, insomnia, irritability, depression
Hyperpigmentation — ACTH activates MC1R on melanocytes; darkening of skin creases, gums, scars
HPA axis suppression — endogenous ACTH production decreases; risk of adrenal insufficiency upon withdrawal
Adrenal hypertrophy — chronic stimulation enlarges adrenal glands

Risk increases with dose and duration. A few low-dose administrations over 2 weeks carry far less risk than daily use over months. The side effects above are primarily associated with chronic cortisol excess. Single or infrequent low-dose administrations may produce measurable cortisol elevation without Cushingoid effects. The key is keeping total cortisol exposure within physiological limits — which requires monitoring.

Contraindications

Active Cushing's syndrome or cortisol excess — ACTH will worsen cortisol elevation in individuals already producing too much cortisol
Uncontrolled diabetes mellitus — cortisol raises blood glucose; ACTH administration can destabilize glycemic control
Uncontrolled hypertension — cortisol increases blood pressure through sodium retention and vascular effects
Active systemic infections — cortisol suppresses immune function; ACTH-stimulated cortisol elevation during active infection is dangerous
Osteoporosis or bone density concerns — cortisol accelerates bone loss
Pregnancy and breastfeeding — cortisol elevation can affect fetal development and reproductive hormone balance; avoid entirely
Known hypersensitivity to Cosyntropin — allergic reactions, while rare with synthetic Cosyntropin, are possible
Psychiatric conditions sensitive to cortisol — cortisol elevation can worsen anxiety, depression, and psychosis

When to Stop Immediately

Rapid weight gain, facial puffiness, or abdominal swelling (signs of cortisol excess)
Fasting blood glucose consistently above normal range (cortisol-induced hyperglycemia)
New-onset or worsening hypertension
Significant mood changes — new anxiety, insomnia, or depressive symptoms
Skin changes — new hyperpigmentation, thinning, or unusual bruising
Signs of infection — cortisol suppresses immunity; new infections while on ACTH warrant immediate discontinuation
Any allergic reaction — rash, hives, throat tightness, difficulty breathing

Regulatory Status: Cosyntropin (Cortrosyn) is an FDA-approved diagnostic agent for adrenal function testing. It is a prescription medication. Use outside of its approved diagnostic indication is off-label. Full-length ACTH (1–39) preparations are not available as FDA-approved drugs in the United States, though repository corticotropin injection (Acthar Gel) is approved for specific conditions including infantile spasms and certain inflammatory disorders.

Common ACTH Dosing Mistakes

Avoid these critical errors when working with ACTH protocols:

Using ACTH without monitoring cortisol levels: ACTH’s entire mechanism of action is to stimulate cortisol production. Using it without measuring cortisol response is like stepping on the gas pedal without a speedometer — you have no idea how much cortisol you’re generating or whether it’s reaching harmful levels. Always test baseline and post-dose cortisol when using ACTH in any context.

Treating ACTH like a benign peptide with no endocrine consequences: Unlike many research peptides that act on specific localized pathways, ACTH activates the HPA axis — one of the body’s most powerful hormonal systems. Even low doses stimulate real cortisol production with real metabolic, immune, and cardiovascular effects. ACTH is not comparable to BPC-157 or KPV in terms of risk profile. It demands medical oversight.

Using the 250 mcg diagnostic dose for chronic administration: The 250 mcg Cosyntropin stimulation test dose is designed as a single diagnostic event, not a repeated therapeutic dose. It is supraphysiological — approximately 100x the maximal physiological ACTH exposure. Repeated administration at this dose would cause severe sustained cortisol elevation and Cushing’s-like effects. Research protocols exploring ongoing use employ much lower doses (1–50 mcg).

Stopping ACTH abruptly after prolonged use: Chronic ACTH administration suppresses endogenous ACTH production through HPA axis negative feedback. If exogenous ACTH is stopped abruptly, the pituitary may not immediately resume adequate ACTH production, leaving the adrenals unstimulated. This can result in adrenal insufficiency — a potentially dangerous condition. Any protocol lasting more than a few weeks should taper gradually under medical supervision.

Confusing ACTH with direct cortisol replacement (hydrocortisone/prednisone): ACTH stimulates the adrenals to produce cortisol naturally, while hydrocortisone and prednisone are synthetic cortisol that bypass the adrenals entirely. The effects are related but not identical. ACTH also stimulates adrenal production of aldosterone, androgens (DHEA), and other steroid precursors — not just cortisol. Do not assume that ACTH protocols are equivalent to corticosteroid therapy.

Attempting low-dose protocols without proper dilution technique: Cosyntropin typically comes in 250 mcg vials. Achieving a 1 mcg or 10 mcg dose requires precise serial dilution. Errors in dilution technique can result in doses that are 10–100x higher or lower than intended. Use a calibrated syringe, sterile technique, and verify your math. The low-dose Cosyntropin test’s clinical controversy partly stems from inconsistent dilution practices.

Using ACTH for ‘adrenal fatigue’ without proper diagnosis: ‘Adrenal fatigue’ is not a recognized medical diagnosis. True adrenal insufficiency (Addison’s disease, secondary adrenal insufficiency) is diagnosed through formal testing including the Cosyntropin stimulation test. Self-treating perceived ‘adrenal fatigue’ with ACTH can worsen underlying conditions, mask real diagnoses, and create iatrogenic cortisol excess. Get a proper diagnostic workup before considering any ACTH-based protocol.

Ignoring the pigmentation effects of chronic ACTH exposure: ACTH has affinity for the MC1R receptor on melanocytes, in addition to its primary MC2R adrenal target. Chronic ACTH excess causes hyperpigmentation, particularly in skin creases, gums, and sun-exposed areas. This is a clinical hallmark of conditions like Addison’s disease (where endogenous ACTH is chronically elevated). If you notice darkening of skin creases or gums during an ACTH protocol, it indicates excessive melanocortin receptor stimulation and the dose should be reassessed.

Frequently Asked Questions

Key Takeaways

ACTH (1–39) is the pituitary hormone that controls cortisol production — it activates MC2R on adrenal cells to stimulate synthesis of cortisol, aldosterone, and adrenal androgens
Cosyntropin (ACTH 1–24) is the synthetic diagnostic fragment — retains full biological activity; used clinically for the ACTH stimulation test
Standard diagnostic dose: 250 mcg IV or IM — supraphysiological stimulus; cortisol measured at 30 and 60 minutes; normal response ≥18–20 mcg/dL
Low-dose diagnostic: 1 mcg IV — more physiological stimulus; may detect subtle adrenal insufficiency missed by standard test
Research protocols use 5–50 mcg SubQ, 2–3x per week — experimental; not supported by clinical trials; requires cortisol monitoring and medical supervision
Cortisol elevation is the primary effect and primary risk — chronic use can cause Cushing's-like effects, HPA axis suppression, metabolic disruption, and immune suppression
Maximum recommended research protocol: 2–4 weeks — with 4–8 weeks recovery; always taper; never stop abruptly after >2 weeks
Blood testing is mandatory, not optional — monitor cortisol, ACTH, DHEA-S, glucose, blood pressure, and electrolytes throughout any protocol
Not comparable to benign peptides — ACTH is a potent endocrine hormone, not in the same risk category as BPC-157, KPV, or similar research peptides
Medical supervision is required — for any non-diagnostic use; this is a prescription diagnostic agent being used off-label

This article is for educational and informational purposes only. See our Disclaimer.

References

Kazlauskaite R, et al. “Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis.” J Clin Endocrinol Metab. 2008;93(11):4245-4253. PubMed
Dickstein G, et al. “Is there a role for low-dose ACTH stimulation test in the diagnosis of adrenal insufficiency?” Clin Endocrinol (Oxf). 2005;62(4):474-480.
Dorin RI, et al. “Diagnosis of adrenal insufficiency.” Ann Intern Med. 2003;139(3):194-204. PubMed
Bornstein SR, et al. “Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab. 2016;101(2):364-389. PubMed
Catania A, et al. “The melanocortin system in control of inflammation.” ScientificWorldJournal. 2010;10:1840-1853. PubMed
Getting SJ, et al. “Molecular determinants of the anti-inflammatory actions of the melanocortin peptides.” Pharmacol Ther. 2006;111(1):1-15. PubMed
Mountjoy KG, et al. “The cloning of a family of genes that encode the melanocortin receptors.” Science. 1992;257(5074):1248-1251. PubMed
Fleseriu M, et al. “Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab. 2016;101(11):3888-3921. PubMed
Nieman LK. “Cushing's syndrome: update on signs, symptoms and biochemical screening.” Eur J Endocrinol. 2015;173(4):M33-M38. PubMed

Next Steps

Continue your research with these resources.

Thymosin Alpha-1 Dosage Guide

Learn dosing protocols for Thymosin Alpha-1 — the most common immune-modulating stacking partner for adrenal support protocols.

Read Guide

Dosage Calculator

Calculate your exact Cosyntropin dose based on vial size and reconstitution volume — critical for low-dose accuracy.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory